Equity Overview
Price & Market Data
Price: $0.851
Daily Change: -$0.01 / 1.18%
Range: $0.843 - $0.905
Market Cap: $51,884,788
Volume: 103,737
Performance Metrics
1 Week: -4.17%
1 Month: -1.37%
3 Months: -18.17%
6 Months: -5.45%
1 Year: -10.42%
YTD: -10.42%
Company Details
Employees: 10
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics to treat cancer and other serious diseases in the United States. It is developing KB-9558, a p300 KAT inhibitor development candidate which is in preclinical development for the treatment of multiple myeloma, as well as HPV-driven tumors; and KB-7898, a p300 KAT inhibitor, which is in preclinical development for the treatment of Sjogren's disease. The company was incorporated in 2017 and is headquartered in San Mateo, California.